Review



mouse anti human primary antibodies against brca1  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology mouse anti human primary antibodies against brca1
    Representative images of <t>BRCA1</t> and FANCD2 staining in benign and malignant tumor tissues of patients with BC at ×200 magnification. (A) Negative control of BRCA1 in BC tissues. (B) Negative control of FANCD2 in BC tissue. Positive control of BRCA1 in (C) the nuclei and (D) cytoplasm of BC tissue. (E) Positive control of FANCD2 in the nuclei of BC tissues. (F) Positive expression of BRCA1 in the nuclei, (G) BRCA1 in the cytoplasm and (H) FANCD2 in the nuclei of BC tissues. Positive expression of (I) BRCA1 in the nuclei, (J) BRCA1 in the cytoplasm and (K) FANCD2 in the nuclei of the tissues adjacent to the carcinoma. Positive expression of (L) BRCA1 in the nuclei, (M) BRCA1 in the cytoplasm and (N) FANCD2 in the nuclei of benign tissues. (O) Negative expression of FANCD2 in benign tissue. BC, breast cancer; BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.
    Mouse Anti Human Primary Antibodies Against Brca1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1035 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+primary+antibodies+against+brca1/BRCA1+Antibody/pmc06403512-197-29-46
    Average 96 stars, based on 1035 article reviews
    mouse anti human primary antibodies against brca1 - by Bioz Stars, 2026-08
    96/100 stars

    Images

    1) Product Images from "Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer"

    Article Title: Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer

    Journal: Oncology Letters

    doi: 10.3892/ol.2019.10046

    Representative images of BRCA1 and FANCD2 staining in benign and malignant tumor tissues of patients with BC at ×200 magnification. (A) Negative control of BRCA1 in BC tissues. (B) Negative control of FANCD2 in BC tissue. Positive control of BRCA1 in (C) the nuclei and (D) cytoplasm of BC tissue. (E) Positive control of FANCD2 in the nuclei of BC tissues. (F) Positive expression of BRCA1 in the nuclei, (G) BRCA1 in the cytoplasm and (H) FANCD2 in the nuclei of BC tissues. Positive expression of (I) BRCA1 in the nuclei, (J) BRCA1 in the cytoplasm and (K) FANCD2 in the nuclei of the tissues adjacent to the carcinoma. Positive expression of (L) BRCA1 in the nuclei, (M) BRCA1 in the cytoplasm and (N) FANCD2 in the nuclei of benign tissues. (O) Negative expression of FANCD2 in benign tissue. BC, breast cancer; BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.
    Figure Legend Snippet: Representative images of BRCA1 and FANCD2 staining in benign and malignant tumor tissues of patients with BC at ×200 magnification. (A) Negative control of BRCA1 in BC tissues. (B) Negative control of FANCD2 in BC tissue. Positive control of BRCA1 in (C) the nuclei and (D) cytoplasm of BC tissue. (E) Positive control of FANCD2 in the nuclei of BC tissues. (F) Positive expression of BRCA1 in the nuclei, (G) BRCA1 in the cytoplasm and (H) FANCD2 in the nuclei of BC tissues. Positive expression of (I) BRCA1 in the nuclei, (J) BRCA1 in the cytoplasm and (K) FANCD2 in the nuclei of the tissues adjacent to the carcinoma. Positive expression of (L) BRCA1 in the nuclei, (M) BRCA1 in the cytoplasm and (N) FANCD2 in the nuclei of benign tissues. (O) Negative expression of FANCD2 in benign tissue. BC, breast cancer; BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.

    Techniques Used: Staining, Negative Control, Positive Control, Expressing

    Expression of BRCA1 and FANCD2, and clinical characteristics of patients with BC.
    Figure Legend Snippet: Expression of BRCA1 and FANCD2, and clinical characteristics of patients with BC.

    Techniques Used: Expressing

    Comparisons of (A) BRCA1 and (B) FANCD2 expression levels between breast cancer tissues and non-cancerous adjacent tissues. The red bar represents the tumor tissues and the gray bar indicates the non-cancerous adjacent tissues. These figures were derived from the Gene Expression Profiling Interactive Analysis dataset. *P<0.05. BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.
    Figure Legend Snippet: Comparisons of (A) BRCA1 and (B) FANCD2 expression levels between breast cancer tissues and non-cancerous adjacent tissues. The red bar represents the tumor tissues and the gray bar indicates the non-cancerous adjacent tissues. These figures were derived from the Gene Expression Profiling Interactive Analysis dataset. *P<0.05. BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.

    Techniques Used: Expressing, Derivative Assay, Gene Expression

    Expression of BRCA1 and FANCD2, and clinical characteristics of patients with breast cancer obtained from The Cancer Genome Atlas dataset.
    Figure Legend Snippet: Expression of BRCA1 and FANCD2, and clinical characteristics of patients with breast cancer obtained from The Cancer Genome Atlas dataset.

    Techniques Used: Expressing

    DFS of patients with breast cancer based on BRCA1 and FANCD2 expression. DFS of patients with FBC grouped by positive or negative expression of (A) BRCA1 and (B) FANCD2. DFS of patients with SBC were divided by positive or negative expression of (C) BRCA1 and (D) FANCD2. Probabilities of DFS were estimated using the Kaplan-Meier method and compared using the log-rank statistic. BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; Cum, cumulative; DFS, disease-free survival; FBC, familial breast cancer; SBC, sporadic breast cancer.
    Figure Legend Snippet: DFS of patients with breast cancer based on BRCA1 and FANCD2 expression. DFS of patients with FBC grouped by positive or negative expression of (A) BRCA1 and (B) FANCD2. DFS of patients with SBC were divided by positive or negative expression of (C) BRCA1 and (D) FANCD2. Probabilities of DFS were estimated using the Kaplan-Meier method and compared using the log-rank statistic. BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; Cum, cumulative; DFS, disease-free survival; FBC, familial breast cancer; SBC, sporadic breast cancer.

    Techniques Used: Expressing

    Univariable and multivariable analyses of disease-free survival in the two groups of patients with breast cancer.
    Figure Legend Snippet: Univariable and multivariable analyses of disease-free survival in the two groups of patients with breast cancer.

    Techniques Used:

    Western blot analysis of FANCD2 in patients with SBC. FANCD2 is represented by two adjacent bands. The upper stripe, L, is ubiquitinated FANCD2, and the lower stripe, S, is unubiquitinated FANCD2. Western blotting from the other 50 patients are shown in . BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein.
    Figure Legend Snippet: Western blot analysis of FANCD2 in patients with SBC. FANCD2 is represented by two adjacent bands. The upper stripe, L, is ubiquitinated FANCD2, and the lower stripe, S, is unubiquitinated FANCD2. Western blotting from the other 50 patients are shown in . BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein.

    Techniques Used: Western Blot



    Similar Products

    mouse anti human primary antibodies against brca1  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology mouse anti human primary antibodies against brca1
    Representative images of <t>BRCA1</t> and FANCD2 staining in benign and malignant tumor tissues of patients with BC at ×200 magnification. (A) Negative control of BRCA1 in BC tissues. (B) Negative control of FANCD2 in BC tissue. Positive control of BRCA1 in (C) the nuclei and (D) cytoplasm of BC tissue. (E) Positive control of FANCD2 in the nuclei of BC tissues. (F) Positive expression of BRCA1 in the nuclei, (G) BRCA1 in the cytoplasm and (H) FANCD2 in the nuclei of BC tissues. Positive expression of (I) BRCA1 in the nuclei, (J) BRCA1 in the cytoplasm and (K) FANCD2 in the nuclei of the tissues adjacent to the carcinoma. Positive expression of (L) BRCA1 in the nuclei, (M) BRCA1 in the cytoplasm and (N) FANCD2 in the nuclei of benign tissues. (O) Negative expression of FANCD2 in benign tissue. BC, breast cancer; BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.
    Mouse Anti Human Primary Antibodies Against Brca1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+primary+antibodies+against+brca1/BRCA1+Antibody/pmc06403512-197-29-46
    Average 96 stars, based on 1 article reviews
    mouse anti human primary antibodies against brca1 - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Representative images of BRCA1 and FANCD2 staining in benign and malignant tumor tissues of patients with BC at ×200 magnification. (A) Negative control of BRCA1 in BC tissues. (B) Negative control of FANCD2 in BC tissue. Positive control of BRCA1 in (C) the nuclei and (D) cytoplasm of BC tissue. (E) Positive control of FANCD2 in the nuclei of BC tissues. (F) Positive expression of BRCA1 in the nuclei, (G) BRCA1 in the cytoplasm and (H) FANCD2 in the nuclei of BC tissues. Positive expression of (I) BRCA1 in the nuclei, (J) BRCA1 in the cytoplasm and (K) FANCD2 in the nuclei of the tissues adjacent to the carcinoma. Positive expression of (L) BRCA1 in the nuclei, (M) BRCA1 in the cytoplasm and (N) FANCD2 in the nuclei of benign tissues. (O) Negative expression of FANCD2 in benign tissue. BC, breast cancer; BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.

    Journal: Oncology Letters

    Article Title: Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer

    doi: 10.3892/ol.2019.10046

    Figure Lengend Snippet: Representative images of BRCA1 and FANCD2 staining in benign and malignant tumor tissues of patients with BC at ×200 magnification. (A) Negative control of BRCA1 in BC tissues. (B) Negative control of FANCD2 in BC tissue. Positive control of BRCA1 in (C) the nuclei and (D) cytoplasm of BC tissue. (E) Positive control of FANCD2 in the nuclei of BC tissues. (F) Positive expression of BRCA1 in the nuclei, (G) BRCA1 in the cytoplasm and (H) FANCD2 in the nuclei of BC tissues. Positive expression of (I) BRCA1 in the nuclei, (J) BRCA1 in the cytoplasm and (K) FANCD2 in the nuclei of the tissues adjacent to the carcinoma. Positive expression of (L) BRCA1 in the nuclei, (M) BRCA1 in the cytoplasm and (N) FANCD2 in the nuclei of benign tissues. (O) Negative expression of FANCD2 in benign tissue. BC, breast cancer; BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.

    Article Snippet: Tissues were blocked with 1% bovine serum albumin (Reagent A, KIT-9710 UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit, MXB Biotechnology) at room temperature to avoid non-specific binding, and labeled with the mouse anti-human primary antibodies against BRCA1 (cat. no. sc-56030; 1:200) and FANCD2 (cat. no. sc-20022; 1:150) (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

    Techniques: Staining, Negative Control, Positive Control, Expressing

    Expression of BRCA1 and FANCD2, and clinical characteristics of patients with BC.

    Journal: Oncology Letters

    Article Title: Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer

    doi: 10.3892/ol.2019.10046

    Figure Lengend Snippet: Expression of BRCA1 and FANCD2, and clinical characteristics of patients with BC.

    Article Snippet: Tissues were blocked with 1% bovine serum albumin (Reagent A, KIT-9710 UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit, MXB Biotechnology) at room temperature to avoid non-specific binding, and labeled with the mouse anti-human primary antibodies against BRCA1 (cat. no. sc-56030; 1:200) and FANCD2 (cat. no. sc-20022; 1:150) (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

    Techniques: Expressing

    Comparisons of (A) BRCA1 and (B) FANCD2 expression levels between breast cancer tissues and non-cancerous adjacent tissues. The red bar represents the tumor tissues and the gray bar indicates the non-cancerous adjacent tissues. These figures were derived from the Gene Expression Profiling Interactive Analysis dataset. *P<0.05. BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.

    Journal: Oncology Letters

    Article Title: Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer

    doi: 10.3892/ol.2019.10046

    Figure Lengend Snippet: Comparisons of (A) BRCA1 and (B) FANCD2 expression levels between breast cancer tissues and non-cancerous adjacent tissues. The red bar represents the tumor tissues and the gray bar indicates the non-cancerous adjacent tissues. These figures were derived from the Gene Expression Profiling Interactive Analysis dataset. *P<0.05. BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.

    Article Snippet: Tissues were blocked with 1% bovine serum albumin (Reagent A, KIT-9710 UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit, MXB Biotechnology) at room temperature to avoid non-specific binding, and labeled with the mouse anti-human primary antibodies against BRCA1 (cat. no. sc-56030; 1:200) and FANCD2 (cat. no. sc-20022; 1:150) (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

    Techniques: Expressing, Derivative Assay, Gene Expression

    Expression of BRCA1 and FANCD2, and clinical characteristics of patients with breast cancer obtained from The Cancer Genome Atlas dataset.

    Journal: Oncology Letters

    Article Title: Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer

    doi: 10.3892/ol.2019.10046

    Figure Lengend Snippet: Expression of BRCA1 and FANCD2, and clinical characteristics of patients with breast cancer obtained from The Cancer Genome Atlas dataset.

    Article Snippet: Tissues were blocked with 1% bovine serum albumin (Reagent A, KIT-9710 UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit, MXB Biotechnology) at room temperature to avoid non-specific binding, and labeled with the mouse anti-human primary antibodies against BRCA1 (cat. no. sc-56030; 1:200) and FANCD2 (cat. no. sc-20022; 1:150) (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

    Techniques: Expressing

    DFS of patients with breast cancer based on BRCA1 and FANCD2 expression. DFS of patients with FBC grouped by positive or negative expression of (A) BRCA1 and (B) FANCD2. DFS of patients with SBC were divided by positive or negative expression of (C) BRCA1 and (D) FANCD2. Probabilities of DFS were estimated using the Kaplan-Meier method and compared using the log-rank statistic. BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; Cum, cumulative; DFS, disease-free survival; FBC, familial breast cancer; SBC, sporadic breast cancer.

    Journal: Oncology Letters

    Article Title: Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer

    doi: 10.3892/ol.2019.10046

    Figure Lengend Snippet: DFS of patients with breast cancer based on BRCA1 and FANCD2 expression. DFS of patients with FBC grouped by positive or negative expression of (A) BRCA1 and (B) FANCD2. DFS of patients with SBC were divided by positive or negative expression of (C) BRCA1 and (D) FANCD2. Probabilities of DFS were estimated using the Kaplan-Meier method and compared using the log-rank statistic. BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; Cum, cumulative; DFS, disease-free survival; FBC, familial breast cancer; SBC, sporadic breast cancer.

    Article Snippet: Tissues were blocked with 1% bovine serum albumin (Reagent A, KIT-9710 UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit, MXB Biotechnology) at room temperature to avoid non-specific binding, and labeled with the mouse anti-human primary antibodies against BRCA1 (cat. no. sc-56030; 1:200) and FANCD2 (cat. no. sc-20022; 1:150) (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

    Techniques: Expressing

    Univariable and multivariable analyses of disease-free survival in the two groups of patients with breast cancer.

    Journal: Oncology Letters

    Article Title: Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer

    doi: 10.3892/ol.2019.10046

    Figure Lengend Snippet: Univariable and multivariable analyses of disease-free survival in the two groups of patients with breast cancer.

    Article Snippet: Tissues were blocked with 1% bovine serum albumin (Reagent A, KIT-9710 UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit, MXB Biotechnology) at room temperature to avoid non-specific binding, and labeled with the mouse anti-human primary antibodies against BRCA1 (cat. no. sc-56030; 1:200) and FANCD2 (cat. no. sc-20022; 1:150) (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

    Techniques:

    Western blot analysis of FANCD2 in patients with SBC. FANCD2 is represented by two adjacent bands. The upper stripe, L, is ubiquitinated FANCD2, and the lower stripe, S, is unubiquitinated FANCD2. Western blotting from the other 50 patients are shown in . BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein.

    Journal: Oncology Letters

    Article Title: Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer

    doi: 10.3892/ol.2019.10046

    Figure Lengend Snippet: Western blot analysis of FANCD2 in patients with SBC. FANCD2 is represented by two adjacent bands. The upper stripe, L, is ubiquitinated FANCD2, and the lower stripe, S, is unubiquitinated FANCD2. Western blotting from the other 50 patients are shown in . BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein.

    Article Snippet: Tissues were blocked with 1% bovine serum albumin (Reagent A, KIT-9710 UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit, MXB Biotechnology) at room temperature to avoid non-specific binding, and labeled with the mouse anti-human primary antibodies against BRCA1 (cat. no. sc-56030; 1:200) and FANCD2 (cat. no. sc-20022; 1:150) (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

    Techniques: Western Blot